secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211922
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026
--------------------------------------------------------------------------------

- Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.
- Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.
- Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.
- Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.
- Cash runway projected into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/0001193125-26-211922-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/asmb-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211922

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer